Insys' Cannabidiol Gets Orphan Drug Designation For Pediatric Schizophrenia

Insys Therapeutics, Inc. (
), a specialty pharmaceutical company, Monday said that the U.S. Food and Drug Administration has designated its drug candidate Cannabidiol as an Orphan Drug to treat Pediatric Schizophrenia.

Pediatric schizophrenia is a severe brain disorder that causes a child to interpret reality abnormally and has a profound impact on a child’s behavior and development. The designation allows the company to enjoy seven years of U.S. marketing exclusivity for the drug upon approval, along with other additional incentives.

The company expects to conduct the phase 1 clinical trial to test the drug in humans, in early 2015.

Read more:


Has anybody smoked indica marijuana in the past (DON’T IF YOU HAVE PSYCHOSIS)? There is an aspect of its effects that feels calming and somewhat grounding/normal feeling. Hopefully this isolated drug is what causes the good part of smoking marijuana, the almost sanity, without that THC that causes episodes. I’m excited for progress in this treatment of our illness.

For the sake of safety regarding my response here, this drug sounds promising for treating schizophrenia; however, stay away from smoking pot!

1 Like